Abstract:Adenosine monophosphate-activated protein kinase (AMPK) is a principal regulator of metabolism and the conservation of energy in cells, and protects them from exposure to various stressors. AMPK activators may exhibit therapeutic potential as suppressors of cell growth; however, the molecular mechanism underlying this phenomenon in various cancer cells remains to be fully elucidated. The present study investigated the effects of AMPK activators on breast cancer cell growth and specified the underlying molecular mechanism. In the present study, the AMPK activator metformin impaired breast cancer cell growth by reducing dishevelled segment polarity protein 3 (DVL3) and β‑catenin levels. Western blotting and immunohistochemistry demonstrated that DVL3 was recurrently upregulated in breast cancer cells that were not treated with metformin, and was significantly associated with enhanced levels of β‑catenin, c‑Myc and cyclin D1. Overexpression of DVL3 resulted in upregulation of β‑catenin and amplification of breast cancer cell growth, which confirmed that Wnt/β‑catenin activation via DVL3 is associated with breast cancer oncogenesis. To elucidate the underlying mechanism of these effects, the present study verified that metformin resulted in a downregulation of DVL3 and β‑catenin in a dose‑dependent manner, and induced phosphorylation of AMPK. Compound C is an AMPK inhibitor, which when administered alongside metformin, significantly abolished the effects of metformin on the reduction of DVL3 and activation of the phosphorylation of AMPK. Notably, the effects of metformin on the mRNA expression levels of DVL3 remain to be fully elucidated; however, a possible interaction with DVL3 at the post‑transcriptional level was observed. It has previously been suggested that the molecular mechanism underlying AMPK activator‑induced suppression of breast cancer cell growth involves an interaction with, and impairment of, DVL3 proteins. The results of the present study are of future clinical importance and advocate the use of metformin as a potential therapeutic agent against breast cancer.

LKB1/AMPK inhibits TGF-β1 production and the TGF-β signaling pathway in breast cancer cells

AMPK Inhibits the Stimulatory Effects of TGF-β on Smad2/3 Activity, Cell Migration, and Epithelial-to-Mesenchymal Transition.

AMPK Inhibits Smad3‐mediated Autoinduction of TGF‐β1 in Gastric Cancer Cells

AMPK Activators Suppress Breast Cancer Cell Growth by Inhibiting DVL3-facilitated Wnt/β-catenin Signaling Pathway Activity.

Negative Regulation of Bmi-1 by AMPK and Implication in Cancer Progression.

AMP‐activated Protein Kinase Regulates Cancer Cell Growth and Metabolism Via Nuclear and Mitochondria Events

AMPK as a metabolic tumor suppressor: control of metabolism and cell growth

Metformin is a Novel Suppressor for Transforming Growth Factor (Tgf)-Β1.

Activation of AMPK Inhibits TGF-β1-induced Airway Smooth Muscle Cells Proliferation and Its Potential Mechanisms

Negative Regulation Of Tgf-Beta By Ampk And Implications In The Treatment Of Associated Disorders

Metformin inhibits growth of human non‑small cell lung cancer cells via liver kinase B‑1‑independent activation of adenosine monophosphate‑activated protein kinase

Activation of AMPK by metformin inhibits TGF-β-induced collagen production in mouse renal fibroblasts

Metformin Inhibits ALK1-mediated Angiogenesis Via Activation of AMPK

Metformin suppresses HIF-1α expression in cancer-associated fibroblasts to prevent tumor-stromal cross talk in breast cancer.

Metformin suppresses HIF-1 expression in cancer-associated fibroblasts to prevent tumor-stromal cross talk in breast cancer

AMP-activated Protein Kinase Suppresses the in Vitro and in Vivo Proliferation of Hepatocellular Carcinoma.

Targeting AMPK for cancer prevention and treatment.

AMPK Inhibition Suppresses the Malignant Phenotype of Pancreatic Cancer Cells in Part by Attenuating Aerobic Glycolysis

Proteomes from AMPK-inhibited peripheral blood mononuclear cells suppress the progression of breast cancer and bone metastasis

FAF1 Phosphorylation by AKT Accumulates TGF-β Type II Receptor and Drives Breast Cancer Metastasis

Metformin Suppresses Proliferation and Invasion of Drug‐resistant Breast Cancer Cells by Activation of the Hippo Pathway